Boston Scientific (NYSE:BSX) Given New $115.00 Price Target at Mizuho

Boston Scientific (NYSE:BSX) had its price target cut by Mizuho from $140.00 to $115.00 in a research note released on Thursday, Marketbeat.com reports. They currently have an outperform rating on the medical equipment provider’s stock.

Several other equities analysts have also recently issued reports on the stock. Wells Fargo & Company boosted their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Royal Bank Of Canada lifted their price objective on Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Citigroup reduced their target price on Boston Scientific from $130.00 to $102.00 and set a “buy” rating on the stock in a report on Thursday. Oppenheimer lowered their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday, January 16th. Finally, Evercore ISI set a $112.00 price target on Boston Scientific in a research note on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $109.32.

Boston Scientific Price Performance

Shares of BSX stock opened at $77.60 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific has a fifty-two week low of $74.86 and a fifty-two week high of $109.50. The firm has a market cap of $115.04 billion, a P/E ratio of 40.00, a P/E/G ratio of 1.33 and a beta of 0.67. The business’s 50 day moving average price is $93.90 and its 200-day moving average price is $98.98.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The firm’s revenue was up 15.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities research analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.50% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds have recently added to or reduced their stakes in the company. State Street Corp increased its position in Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares during the last quarter. Synergy Asset Management LLC boosted its stake in shares of Boston Scientific by 3,493.0% during the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock worth $48,297,000 after purchasing an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC grew its holdings in Boston Scientific by 39.5% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after purchasing an additional 14,700 shares during the last quarter. Channel Wealth LLC raised its position in Boston Scientific by 70.8% in the 3rd quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider’s stock worth $2,790,000 after purchasing an additional 11,847 shares during the period. Finally, Bank of Nova Scotia lifted its stake in Boston Scientific by 106.4% in the second quarter. Bank of Nova Scotia now owns 3,025,519 shares of the medical equipment provider’s stock worth $324,971,000 after purchasing an additional 1,559,605 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat Wall Street: Boston Scientific reported $0.80 EPS and $5.29B in sales (sales +15.9%), showing solid underlying growth that supports the company’s long-term story. PR: Q4 results
• Positive Sentiment: Analysts still mostly constructive: Many firms kept buy/overweight ratings and continue to model meaningful upside even after trimming forecasts — that backing can attract buyers after the drop. Benzinga: analysts cutting forecasts
• Neutral Sentiment: Planned board departure announced — a governance change (long‑serving director stepping down) that is notable but not an operational shock. TipRanks: board departure
• Neutral Sentiment: Unusual options activity and heavy put buying increased volatility — option flows amplified the move and can accelerate selloffs or rebounds depending on market makers’ hedging. Barchart: options activity
• Negative Sentiment: Soft 2026 guidance and underperformance in electrophysiology: management gave a cautious revenue/quarterly outlook and flagged weaker EP sales, which triggered the earlier large selloff as it reset near-term growth expectations. Reuters: cautious outlook
• Negative Sentiment: Multiple price-target cuts: several banks trimmed targets (some steeply) after the print — that lowers analyst floor and can weigh on recovery momentum. Benzinga: PT cuts
• Negative Sentiment: New investor class-action inquiry: Levi & Korsinsky announced an investigation into BSX related to the Feb. 4 results, which is a legal overhang until resolved. Newsfile: securities probe
• Negative Sentiment: CEO insider sale disclosed (large block sold in early Feb.) — raises near‑term sentiment concerns even if not unusual for executives. SEC filing: insider sale

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.